Evidence map›Paper›PMID 28974973›Full record

ArticleResearch in pharmaceutical sciences2017

Facile one-pot four-component synthesis of 3,4-dihydro-2-pyridone derivatives: novel urease inhibitor scaffold.

Arash Modarres Hakimi, Negar Lashgari, Shabnam Mahernia, Ghodsi Mohammadi Ziarani, Massoud Amanlou

Open access · goldAbstract read
In one paragraph

Article in Research in pharmaceutical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. 3,4-Dihydro-2(1Molecules (Basel, Switzerland) · 2022
    Review
  2. Nano-SnClResearch in pharmaceutical sciences · 2019
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Arash Modarres HakimiDrug Design & Development Research Centre and Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, I.R. Iran.
Negar LashgariSchool of Chemistry, College of Science, University of Tehran, Tehran, I.R. Iran.
Shabnam MaherniaDrug Design & Development Research Centre and Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, I.R. Iran.
Ghodsi Mohammadi ZiaraniDepartment of Chemistry, Alzahra University, Tehran, I.R. Iran.
Massoud AmanlouDrug Design & Development Research Centre and Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, I.R. Iran.
Alzahra University · IRUniversity of Tehran · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current study, a series of 3,4-dihydro-2-pyridone derivatives were synthesized in a one-pot fourcomponent reaction of Meldrum's acid, benzaldehyde derivatives, methyl acetoacetate, and ammonium acetate. SiO2-Pr-SO3H was used as an efficient catalyst for the synthesis of the target compounds under solvent-free conditions. The most probable mechanism for this reaction has been discussed. The advantages of this methodology are high product yields, being environmentally benign, short reaction times, and easy handling. Eight 2-pyridinone derivatives were evaluated for their inhibitory activities against Jack bean urease. Molecular docking study of the synthesized compounds was also evaluated. All compounds showed good activities against urease and among them, 4-(4-nitrophenyl)-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (

Indexed as

3,4-Dihydro-2-pyridone derivativesMulticomponent reactionSiO2-Pr-SO3HUrease inhibitory activity

Identifiers

PMID28974973
PMCPMC5615865
OpenAlexW2752179487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.